For the Culture By The Culture
Celebrity weed is everywhere, flashy, overpriced, and often full of mids. This piece rips the gloss off the jars and calls out the marketing machine hijacking cannabis culture. Real smokers know the difference between herb and hype. This is your wake-up call.
Legacy growers fought for legalization, only to be pushed aside by the system they helped create. This feature exposes how red tape, taxes, and policy failures are locking out the real pioneers while corporate weed cashes in. It’s not just exclusion—it’s cultural erasure. And if we’re not careful, the soul of cannabis will vanish under glossy branding and mediocre bud.
Colorado just lost $20 million in cannabis sales, and it’s not a fluke. From hemp loopholes to collapsing tourism, this feature investigates what’s really behind the budget cuts and how the cracks in Colorado’s cannabis economy could foreshadow a national unraveling. If the “gold standard” of legalization is struggling, what does that mean for everyone else?
California just raised taxes on legal cannabis by 26%, threatening to wipe out the small businesses and legacy growers who built the market. This feature breaks down how the policy is pushing operators out, fueling the illicit trade, and revealing the hypocrisy of a state that once championed cannabis culture but now treats it like a cash cow. This is economic betrayal in real time.
May isn’t just a month of planting. It’s a season of rebellion. This cover story digs into the deep roots of cannabis activism, labor, and legacy. From May Day to World Bee Day, we explore the voices and movements that shaped cannabis culture long before legalization. Because rebellion isn’t a moment—it’s the soil this industry grew from.
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.
